medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2021, Number 4

<< Back Next >>

Rev Latin Infect Pediatr 2021; 34 (4)

Immunization with pneumococcal conjugate vaccine and other recommended vaccines in high-risk pediatric patients

Ortiz-Ibarra FJ, Xóchihua DL, González SN, Chacón SJC, Luévanos VA, Otero MFJ, Merlo PM, Ortiz-Casas B, Ramírez UN, Rodríguez BE, Wakida KGH, Camacho-Moreno G, Espinosa RF

Language: Spanish
References: 48
Page: 162-176
PDF size: 346.95 Kb.


ABSTRACT

Immunocompromised patients are of the most affected groups, with the highest mortality rates associated with invasive infections. Due to this, vaccination of immunocompromised patients plays a critical role in improving both survival and quality of life. Since the safety and efficacy of these immunogens will depend on the type and degree of individual immunosuppression, it is relevant to know which are the most indicated vaccines, and which are the contraindicated ones that may present a health risk for these patients. Therefore, this consensus aimed to analyze and discuss the impact of pneumococcal vaccination, as well as other vaccines currently recommended for high-risk pediatric patients. Material and methods: An academic consensus model was used, where the available clinical literature was systematically discussed. For this, both the Guidelines for the development of consensus and the recommendations and criteria of the European AGREE initiated were used. For the formation of the consensus group, mixed and representative teams were integrated by pediatricians, infectious diseases specialists, immunologists, and allergists participated; as well as pediatricians from the private sector. Articles within the period from January 2015 to August 2021 were further selected. Results: A total of 10 relevant points were approached as questions, and a series of recommendations were established based on the critical literature analysis.


REFERENCES

  1. Bazán V, Castellano V, Lamy P, Nolte F, Pacchiotti A, Aversa L et al. Guía de vacunación en huéspedes especiales. Rev Hosp Niños. 2018; 60 (268): 96-110.

  2. Altered Immunocompetence. General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available in: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html

  3. Froneman C, Kelleher P, José RJ. Pneumococcal vaccination in immunocompromised hosts: an update. Vaccines (Basel). 2021; 9 (6): 536. doi: 10.3390/vaccines9060536.

  4. Ortiz-Ibarra FJ, Luévanos-Velázquez A, González SN, Reyna-Figueroa J, Chacón CE, Echaniz AG et al. Consenso de la Asociación Mexicana de Infectología Pediátrica (AMIP) sobre el impacto de la vacunación en la disminución de la carga de enfermedad neumocócica en México, 2018. Rev Latin Infect Pediatr. 2018; 31: 62-75.

  5. Xochihua-Díaz L, Ortiz-Ibarra FJ, González Saldaña N. Streptococcus pneumoniae: recomendaciones de un panel de expertos, AMIP 2020. Rev Latin Infect Pediatr. 2021; 34 (1): 17-19.

  6. Ferrario C, Califano G, Durán P, Maccarone M, Miceli I, Manterola A et al. Lineamientos para la elaboración de consensos. Arch Argent Pediatr. 2012; 110 (2): 163-167. doi: org/10.5546/aap.2012.163.

  7. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. Available in: https://www.agreetrust.org/resource-centre/the-originalagree-instrument/

  8. Manterola C, Asenio-Lobos C, Otze T. Jerarquización de la evidencia. Niveles de evidencia y grados de recomendación de uso actual. Rev Chilena Infectol. 2014; 31: 705-718.

  9. Dulek DE, de St Maurice A, Halasa NB. Vaccines in pediatric transplant recipients-Past, present, and future. Pediatr Transplant. 2018; 22 (7): e13282. doi: 10.1111/petr.13282.

  10. Moore DL. Immunization of the immunocompromised child: key principles. Paediatr Child Health. 2018; 23 (3): 203-205. doi: 10.1093/pch/pxx180.

  11. Manual de Vacunación 2017 Centro Nacional para la Salud de la Infancia y la Adolescencia. Disponible en: http://bit.ly/2n1vF8S

  12. Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009; 360: 244-256.

  13. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time- series analysis. Lancet. 2007; 369: 1179-1186.

  14. Danziger-Isakov L, Kotton CN. Vaccination in organ transplant patients. In: Safdar A (eds). Principles and practice of transplant infectious diseases. New York, NY: Springer; 2019.

  15. Weber T, Ljungman P. Stringent vaccination of cancer patients: is it that important? Ann Oncol. 2018; 29 (6): 1348-1349.

  16. Chilson E, Scott DA, Schmoele-Thoma B, Watson W, Moran MM, Isturiz R. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence. Hum Vaccin Immunother. 2020; 16 (11): 2758-2772.

  17. Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB, Ryan AL et al. Immunogenicity and safety of single dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients. Cancer. 2017; 123: 4215-4221.

  18. Jallow S, Madhi SA, Madimabe R, Sipambo N, Violari A, Kala U et al. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying conditions. Vaccine. 2017; 35 (34): 4321-4329.

  19. Soto-Noguerón A, Carnalla-Barajas NM, Cornejo-Juárez P, Volkow-Fernández P, Velázquez-Meza ME, Echániz-Aviles G. Streptococcus pneumoniae: distribution of serotypes and antimicrobial susceptibility in patients with cancer. Salud Pública Mex. 2018; 60 (1): 21-28.

  20. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax. 2015; 70: 984-989.

  21. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017; 1 (1): CD001390. doi: 10.1002/14651858.CD001390.pub4.

  22. Snijders D, Masiero S, Da Dalt L, Barbato A. Did the introduction of pneumococcal vaccination in Italy change the BAL positive cultures in children with chronic lung diseases? Eur Respir J. 2016; 48 (suppl 60): PA3145. doi: 10.1183/13993003.congress-2016.PA3145.

  23. Esposito S, Colombo C, Tosco A, Montemitro E, Volpi S, Ruggiero L et al. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis. J Cyst Fibros. 2016; 15 (3): 366-371.

  24. Zaidi SR, Blakey JD. Why are people with asthma susceptible to pneumonia? A review of factors related to upper airway bacteria. Respirology. 2019; 24: 423-430.

  25. Bisgaard H. The copenhagen prospective study on asthma in childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study. Ann Allergy Asthma Immunol. 2004; 93 (4): 381-389. doi: 10.1016/S1081-1206(10)61398-1.

  26. Eisenlohr CP, Chartrand EM, Barzaga MR, Lanz MJ. Impact of pneumococcal vaccine response on asthma exacerbation frequency in young children. Immun Inflamm Dis. 2020; 8 (4): 493-496. doi: 10.1002/iid3.331.

  27. Murray CS, Jackson DJ, Teague WG. Prevention and outpatient treatment of asthma exacerbations in children. J Allergy Clin Immunol Pract. 2021; 9 (7): 2567-2576. doi: 10.1016/j.jaip.2021.03.035. Erratum in: J Allergy Clin Immunol Pract. 2021; 9 (10): 3851.

  28. CDC. Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2021. Available in: https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html

  29. Luévanos Velázquez A, Mascareñas de los Santos A, González Saldaña N, Ortiz Ibarra FJ, Romero Feregrino R, Vázquez Narváez JA et al. Esquema de vacunación recomendado para niños de cero a 12 años en México (2018-2019) Asociación Mexicana de Infectología Pediátrica, AC. Rev Latin Infect Pediatr. 2018; 31 (3): 93-9694.

  30. Gutiérrez-Robledo LM, Caro-López E, Guerrero-Almeida ML, Dehesa-Violante M, Rodríguez-Noriega E, García-Lara JM et al. Resultados del Primer Consenso Mexicano de Vacunación en el Adulto. Gac Med Mex. 2017; 153: 190-204.

  31. Alvarado AR, Udobi K, Berry S, Assmann J, McDonald T, Winfield RD. An opportunity for improvement in trauma care: 8-week booster vaccination adherence among patients after trauma splenectomy. Surgery. 2018; 163 (2): 415-418.

  32. Luu S, Dendle C, Jones P, Ojaimi S, Woolley IJ. Impact of a spleen registry on optimal post-splenectomy vaccination and care. Hum Vaccin Immunother. 2018; 14 (12): 2894-2899.

  33. Rubin LG, Levin MJ, Ljungman P et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompro- mised host. Clin Infect Dis. 2014; 58: 309-318.

  34. Espinoza-Mora MR, Lazo-Paez G, León-Bratti MP, Schauer C. Vacunación de pacientes adultos receptores de trasplante de células madre hematopoyéticas. Perspectiva de Costa Rica. Rev Chilena Infectol. 2016; 33 (6): 635-649.

  35. Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15: 1143-1238.

  36. American Society of Hematology. ASH-ASTCT COVID-19 Vaccination for HCT and CAR T Cell Recipients: Frequently Asked Questions. Available in: https://www.hematology.org/covid-19/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients

  37. Le Bourgeois A, Coste-Burel M, Guillaume T et al. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant. JAMA Netw Open. 2021; 4 (9): e2126344. doi: 10.1001/jamanetworkopen.2021.26344.

  38. Nuttall JJ, Eley BS. BCG Vaccination in HIV-infected children. Tuberc Res Treat. 2011; 2011: 712736. doi: 10.1155/2011/712736.

  39. Miranda-Choque Edwin, Candela-Herrera Jorge, R. Segura Eddy, Farfán-Ramos Sonia, Barriga Aldo. Síndrome de reconstitución inmune por BCG en niños tratados por VIH. Rev. perú. med. exp. salud publica [Internet]. 2012 Oct [citado 2021 Dic 01] ; 29( 4 ): 498-502. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342012000400012&lng=es

  40. Kilapandal Venkatraman SM, Sivanandham R, Pandrea I, Apetrei C. BCG Vaccination and mother-to-infant transmission of HIV. J Infect Dis. 2020; 222 (1): 1-3.

  41. Comité Asesor de Vacunas (CAV-AEP). Manual de vacunas en línea de la AEP [Internet]. Madrid: AEP; 2021. Disponible en: http://vacunasaep.org/documentos/manual/manual-de-vacunas

  42. Wysocki J, Brzostek J, Konior R, Panzer FG, Francois NA, Ravula SM et al. Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: results from 2 long-term follow-up studies. Hum Vaccin Immunother. 2017; 13 (3): 661-675.

  43. Wahl B, O'Brien KL, Greenbaum A, Majunder A, Liu L, Chu Y et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018; 6: e744-757.

  44. Adetokunboh OO, Ndwandwe D, Awotiwon A, Uthman OA, Wiysonge CS. Vaccination among HIV-infected, HIV-exposed uninfected and HIV-uninfected children: a systematic review and meta-analysis of evidence related to vaccine efficacy and effectiveness. Hum Vaccin Immunother. 2019; 15 (11): 2578-2589.

  45. Fang X, Henao-Mejia J, Henrickson SE. Obesity and immune status in children. Curr Opin Pediatr. 2020; 32 (6): 805-815. doi: 10.1097/MOP.0000000000000953.

  46. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015; 33 (36): 4422-4429.

  47. Kelishadi R, Roufarshbaf M, Soheili S, Payghambarzadeh F, Masjedi M. Association of childhood obesity and the immune system: a systematic review of reviews. Child Obes. 2017; 13 (4): 332-346. doi: 10.1089/chi.2016.0176.

  48. Sebastian M, Hsiao CJ, Futch HS, Eisinger RS, Dumeny L, Patel S et al. Obesity and STING1 genotype associate with 23-valent pneumococcal vaccination efficacy. JCI Insight. 2020; 5 (9): e136141. doi: 10.1172/jci.insight.136141.




2020     |     www.medigraphic.com